NZ251092A - 4-cyano-cyclohexane derivatives; medicaments; used in treating asthma - Google Patents

4-cyano-cyclohexane derivatives; medicaments; used in treating asthma

Info

Publication number
NZ251092A
NZ251092A NZ251092A NZ25109293A NZ251092A NZ 251092 A NZ251092 A NZ 251092A NZ 251092 A NZ251092 A NZ 251092A NZ 25109293 A NZ25109293 A NZ 25109293A NZ 251092 A NZ251092 A NZ 251092A
Authority
NZ
New Zealand
Prior art keywords
cyano
methoxyphenyl
cyclohexane
alkyl
methyl
Prior art date
Application number
NZ251092A
Other languages
English (en)
Inventor
Siegfried Benjamin Christensen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Priority claimed from SG1996007903A external-priority patent/SG47107A1/en
Publication of NZ251092A publication Critical patent/NZ251092A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/08—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ251092A 1992-04-02 1993-03-05 4-cyano-cyclohexane derivatives; medicaments; used in treating asthma NZ251092A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86203092A 1992-04-02 1992-04-02
US96876292A 1992-10-30 1992-10-30
SG1996007903A SG47107A1 (en) 1992-04-02 1993-03-05 Compounds useful for treating allergic and inflammatory diseases

Publications (1)

Publication Number Publication Date
NZ251092A true NZ251092A (en) 1996-12-20

Family

ID=27356137

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ251092A NZ251092A (en) 1992-04-02 1993-03-05 4-cyano-cyclohexane derivatives; medicaments; used in treating asthma

Country Status (18)

Country Link
US (4) US5552438A (cg-RX-API-DMAC10.html)
EP (1) EP0633776B1 (cg-RX-API-DMAC10.html)
CN (1) CN1066436C (cg-RX-API-DMAC10.html)
AP (2) AP519A (cg-RX-API-DMAC10.html)
AU (1) AU677776B2 (cg-RX-API-DMAC10.html)
BG (1) BG62235B1 (cg-RX-API-DMAC10.html)
CA (1) CA2133439C (cg-RX-API-DMAC10.html)
CZ (1) CZ283425B6 (cg-RX-API-DMAC10.html)
FI (1) FI944549L (cg-RX-API-DMAC10.html)
GR (1) GR3036347T3 (cg-RX-API-DMAC10.html)
HU (1) HU225869B1 (cg-RX-API-DMAC10.html)
IL (1) IL105221A (cg-RX-API-DMAC10.html)
MX (1) MX9301943A (cg-RX-API-DMAC10.html)
NO (1) NO303116B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ251092A (cg-RX-API-DMAC10.html)
SI (1) SI9300169B (cg-RX-API-DMAC10.html)
SK (1) SK279958B6 (cg-RX-API-DMAC10.html)
WO (1) WO1993019749A1 (cg-RX-API-DMAC10.html)

Families Citing this family (240)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0710109B1 (en) * 1993-06-18 2004-09-15 Smithkline Beecham Corporation Method for identifying a PDE IV inhibitor
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
AU7375194A (en) 1993-07-30 1995-02-28 Smithkline Beecham Corporation 3-cyano-3-(3,4-disubstituted)phenylcyclohexyl-1-carboxylates
GB9404706D0 (en) * 1994-03-11 1994-04-27 Smithkline Beecham Corp Compounds
US6013827A (en) * 1994-03-11 2000-01-11 Smithkline Beecham Corporation Compounds
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
US20060019963A1 (en) * 1994-06-17 2006-01-26 Smithkline Beecham Corporation Compounds
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
WO1996019990A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation 4,4-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
JPH10511392A (ja) * 1994-12-23 1998-11-04 スミスクライン・ビーチャム・コーポレイション ４，４−（二置換）シクロヘキサン−１−カルボキシレートダイマーおよび関連化合物
EP0796097A4 (en) * 1994-12-23 1998-03-25 Smithkline Beecham Corp MONOMERS 3.3- (DISUBSTITUTED) CYCLOHEXAN-1-CARBOXYLATE AND CORRESPONDING COMPOUNDS
US5723681A (en) * 1994-12-23 1998-03-03 Smithkline Beecham Corporation 3,3-(disubstituted)cyclohexan-1-01 dimers and related compounds
JPH10511388A (ja) * 1994-12-23 1998-11-04 スミスクライン・ビーチャム・コーポレイション ３，３−（二置換）シクロヘキサン−１−カルボキシレートダイマーおよび関連化合物
DK0828728T3 (da) * 1995-05-18 2003-05-19 Altana Pharma Ag Phenyldihydrobenzofuraner
EP0828727B1 (de) * 1995-05-18 2003-01-02 ALTANA Pharma AG Cyclohexyldihydrobenzofurane
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US5891883A (en) * 1995-12-21 1999-04-06 Smithkline Beecham Corporation 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
EP0934307B1 (en) 1996-06-19 2011-04-27 Aventis Pharma Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
CN1080260C (zh) * 1996-06-25 2002-03-06 美国辉瑞有限公司 取代的吲哚衍生物以及它们作为iv型磷酸二酯酶(pde)和肿瘤坏死因子(tnf)抑制剂的用途
ATE233252T1 (de) * 1996-11-20 2003-03-15 Altana Pharma Ag Substituierte dihydrobenzofurane als pde- hemmstoffe
SI1023279T1 (en) * 1997-02-12 2003-12-31 Smithkline Beecham Corporation Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids
MY118813A (en) * 1997-02-12 2005-01-31 Smithkline Beecham Corp Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids
EP1524268B1 (en) * 1997-02-12 2007-01-17 Smithkline Beecham Corporation Compounds and method for preparing sustituted 4-phenyl-4-cyanocyclohexanoic acids
UA67753C2 (uk) * 1997-10-10 2004-07-15 Смітклайн Бічам Корпорейшн Спосіб отримання заміщених 4-феніл-4-ціанциклогексанових кислот
UY25338A1 (es) 1998-01-07 2001-08-27 Smithkline Beecham Corp Método para tratar copd
WO1999034797A1 (en) * 1998-01-07 1999-07-15 Smithkline Beecham Corporation Method for treating multiple sclerosis
US6118017A (en) * 1998-04-14 2000-09-12 Smithkline Beecham Corporation Substituted-(3-cyclopentyloxy-4-methoxyphenyl)-3-phenylcyanocyclobutan-1-one
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US7811990B2 (en) * 1998-09-25 2010-10-12 Sciaticon Ab Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposus
SE9803710L (sv) * 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
US7115557B2 (en) * 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
US7906481B2 (en) * 1998-09-25 2011-03-15 Sciaticon Ab Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
SK4222001A3 (en) 1998-10-06 2001-10-08 Dainippon Pharmaceutical Co 2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation
AR028986A1 (es) * 1999-02-23 2003-06-04 Smithkline Beecham Corp USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio
DZ3019A1 (fr) * 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
EP1181278B1 (en) * 1999-05-14 2004-09-29 Bristol-Myers Squibb Pharma Research Labs, Inc. Cyclic amine derivatives and their uses
AR024076A1 (es) * 1999-05-25 2002-09-04 Smithkline Beecham Corp Sales de cis-[4-ciano-4-(3-ciclopentiloxi-4-metoxifenil) ciclohexan-1-carboxilato]
ECSP003599A (es) * 1999-08-06 2002-03-25 Smithkline Beecham Corp Procedimiento para preparar acidos a traves de alfa-coroepoxi-esteres
ECSP003600A (es) * 1999-08-06 2002-03-25 Smithkline Beecham Corp Metodo para preparar acidos ciclohexano- carboxilicos
US6740765B1 (en) * 1999-08-06 2004-05-25 Smithkline Beecham Corporation Method for preparing cyclohexane carboxylic acids
US20040220424A1 (en) * 1999-08-06 2004-11-04 Smithkline Beecham Corporation Process for preparing acids via alpha-chloroepoxy esters
SK287231B6 (sk) * 1999-08-21 2010-04-07 Nycomed Gmbh Liečivo zahŕňajúce PDE inhibítor a agonistu beta2 adrenoreceptora
UY26333A1 (es) * 1999-09-15 2001-07-31 Smithkline Beecham Corp Procedimiento e intermedios para preparar ácidos (4-ciano sustituido)- ciclohexanoicos
AR029788A1 (es) * 2000-01-12 2003-07-16 Smithkline Beecham Corp Procedimiento para reducir acidos ciclohexeno carboxilicos alfa,beta-insaturados, procedimiento para preparar acidos 4-nitrilo-4-aril-ciclohexanoicos, procedimiento para preparar acidos ciclohexeno carboxilicos alfa,beta-insaturados, y procedimientos para preparar intermediarios
US20030050497A1 (en) * 2002-07-11 2003-03-13 Webb Kevin Scott Process and intermediates for preparing a cyclohexylnitrile
DK1250313T3 (da) * 2000-01-26 2007-02-12 Smithkline Beecham Corp Monohydrat af cis-lithium-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexancarboxylat
HK1051319A1 (zh) * 2000-02-08 2003-08-01 Smithkline Beecham Corporation 治疗感染疾病的方法和组合物
WO2001060358A1 (en) * 2000-02-16 2001-08-23 University Of Nebraska Medical Center Method and compositions for treating fibrotic diseases
WO2001068600A2 (en) * 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Limited Benzylated pde4 inhibitors
GB0011802D0 (en) * 2000-05-16 2000-07-05 Smithkline Beecham Method for enhancing cognitive function
US20040005995A1 (en) * 2001-07-26 2004-01-08 Edelson Jeffrey D Method for reducing exacerbations associated with copd
ATE416184T1 (de) 2000-08-05 2008-12-15 Glaxo Group Ltd 17.beta.-carbothioat 17.alpha.- arylkarbonyloxyloxy androstanderivate als anti- phlogistische medikamente
US20040224316A1 (en) 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US7250518B2 (en) * 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
CZ20031902A3 (cs) 2001-01-31 2004-07-14 Pfizer Products Inc. Etherové deriváty užitečné jako inhibitory isozymů PDE4
NZ526453A (en) 2001-01-31 2005-01-28 Pfizer Prod Inc Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
OA12542A (en) 2001-01-31 2006-06-05 Pfizer Prod Inc Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4isozymes.
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP4143413B2 (ja) * 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
CN1537018A (zh) * 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
MXPA03010679A (es) * 2001-05-23 2004-03-02 Tanabe Seiyaku Co Una composicion para acelerar la cicatrizacion de fractura osea.
PL393155A1 (pl) * 2001-09-14 2011-03-28 Glaxo Group Limited Pochodne fenetanoloaminy do leczenia chorób układu oddechowego
GB0217199D0 (en) * 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
GB0204719D0 (en) * 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
JP2005523920A (ja) * 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド フェネタノールアミン誘導体
US20030013905A1 (en) * 2002-06-10 2003-01-16 Huang Guishu Kris Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid
GB0217198D0 (en) * 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
GB0217196D0 (en) * 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
EP1554264B1 (en) * 2002-10-22 2007-08-08 Glaxo Group Limited Medicinal arylethanolamine compounds
BR0315720A (pt) 2002-10-28 2005-09-06 Glaxo Group Ltd Composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìmefero, formulação farmacêutica, combinação, uso de um composto, processo para a preparação de um composto, e, intermediário
US20060040981A1 (en) * 2002-11-22 2006-02-23 Daniel Dube Use of phosphodiesterase-4 inhibitors as enhancers of cognition
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0303396D0 (en) * 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
WO2004087211A2 (en) 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
WO2005002626A2 (en) * 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
WO2004098606A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and shuil-1r ii
CA2526730A1 (en) 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
GB0316290D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
DE10331798B4 (de) * 2003-07-14 2012-06-21 Giesecke & Devrient Gmbh Sicherheitselement, Wertgegenstand, Transfermaterial und Herstellungsverfahren
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
GB0324654D0 (en) * 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005095328A1 (en) * 2004-04-02 2005-10-13 Glaxo Group Limited Chemical process and new crystalline form
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
KR101061850B1 (ko) 2004-09-08 2011-09-02 삼성전자주식회사 박막 트랜지스터 표시판 및 그 제조방법
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
ATE517908T1 (de) * 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
US20090124588A1 (en) * 2005-01-10 2009-05-14 Glaxo Group Limited Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
JP2008526805A (ja) * 2005-01-11 2008-07-24 グラクソ グループ リミテッド ベータ−２アドレナリン作動薬のケイヒ酸塩
PE20100737A1 (es) 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP2532678A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
AR058109A1 (es) 2005-12-20 2008-01-23 Glaxo Group Ltd Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US20070203111A1 (en) * 2006-01-06 2007-08-30 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
BRPI0710240A2 (pt) 2006-04-20 2011-08-09 Glaxo Group Ltd composto, uso de um composto, método para o tratamento de um paciente humano ou animal com uma condição ou doença, composição farmacêutica, combinação, e, processo para a preparação de um composto
RU2457209C2 (ru) 2006-04-21 2012-07-27 Новартис Аг Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
BRPI0711816A2 (pt) 2006-05-19 2011-12-13 Helicon Therapeutics Inc inibidores fosfodiesterase 4 para rehabilitação motora e cognitiva
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
PE20080943A1 (es) 2006-06-23 2008-09-27 Smithkline Beecham Corp Sal toluenosulfonato de 4-{[6-cloro-3-({[(2-cloro-3-fluorofenil)amino]carbonil}amino)-2-hidroxifenil]sulfonil}-1-piperazinacarboxilato de 1,1-dimetiletilo como antagonista del receptor de il-8
RS53461B (sr) 2006-07-05 2014-12-31 Takeda Gmbh Kombinacija inhibitora hmg-coa reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja
US20080019975A1 (en) * 2006-07-07 2008-01-24 Bioassets Development Corporation Novel Regimens for Treating Diseases and Disorders
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
CN101657460A (zh) * 2006-12-13 2010-02-24 基利得科学公司 用于治疗肺炎症和支气管收缩的作为抗炎性信号转导调节剂(AISTM’S)和β-激动剂的相互前药的单磷酸酯
DK2104535T3 (da) 2007-01-10 2011-04-04 Irm Llc Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
JP2010523695A (ja) * 2007-04-11 2010-07-15 アルコン リサーチ， リミテッド アレルギー性鼻炎およびアレルギー性結膜炎を処置するためのＴＮＦαのインヒビターおよび抗ヒスタミン薬の使用
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
BRPI0811562A2 (pt) 2007-05-07 2014-12-09 Novartis Ag Compostos orgânicos
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN101679191B (zh) 2007-06-05 2014-03-12 塞诺菲-安万特股份有限公司 二杂芳基环己烷衍生物、其制备方法、用途及含有它们的药用组合物
US7943658B2 (en) * 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
TW200920369A (en) * 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
PT2444120T (pt) 2007-12-10 2018-01-03 Novartis Ag Análogos da amilorida espirocíclicos como bloqueadores de enac
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
EP2285803A4 (en) 2008-05-23 2011-10-05 Amira Pharmaceuticals Inc Inhibitor of 5-Lipoxygenase Activating Protein
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
WO2009150137A2 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010107958A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408915A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2010226604A1 (en) 2009-03-19 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
EP2411019A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411517A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AR076373A1 (es) 2009-04-24 2011-06-08 Glaxo Group Ltd N-pirazolil carboxamidas como inhibidores de canales de calcio
JP2012524754A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
ES2876933T3 (es) 2009-04-30 2021-11-15 Glaxo Group Ltd Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
KR20120089643A (ko) 2009-08-12 2012-08-13 노파르티스 아게 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
PE20170003A1 (es) 2009-08-17 2017-03-15 Intellikine Llc Compuestos heterociclicos y usos de los mismos
IN2012DN01453A (cg-RX-API-DMAC10.html) 2009-08-20 2015-06-05 Novartis Ag
US20110082145A1 (en) * 2009-10-01 2011-04-07 Alcon Research, Ltd. Olopatadine compositions and uses thereof
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
JP2013512880A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
EP3020393B1 (en) 2009-12-16 2020-10-07 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
SI2614058T1 (sl) 2010-09-08 2015-10-30 Glaxosmithkline Intellectual Property Development Limited Polimorfi in soli N-(5-(4-(5-(((2R,6S)-2,6-dimetil-4-morfolinil)metil)-1,3-oksazol-2-il)- 1H-indazol-6-il)-2-(metiloksi)-3-piridinil)metansulfonamida
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
ES2532213T3 (es) 2010-10-21 2015-03-25 Glaxo Group Limited Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias
JP2013544794A (ja) 2010-10-21 2013-12-19 グラクソ グループ リミテッド アレルギー性障害、炎症性障害及び免疫障害に作用するピラゾール化合物
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
EA201391230A1 (ru) 2011-02-25 2014-01-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов trk
CN103764672A (zh) 2011-03-01 2014-04-30 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
WO2012123312A1 (en) 2011-03-11 2012-09-20 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
WO2013084182A1 (en) 2011-12-08 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
CN114404588A (zh) 2013-08-09 2022-04-29 阿德利克斯公司 用于抑制磷酸盐转运的化合物和方法
AU2014321420B2 (en) 2013-09-22 2017-06-15 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
AU2014336250A1 (en) 2013-10-17 2016-04-14 Glaxosmithkline Intellectual Property Development Limited PI3K inhibitor for treatment of respiratory disease
KR20160062178A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
US9403801B2 (en) 2014-03-28 2016-08-02 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
JP6433509B2 (ja) 2014-04-24 2018-12-05 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピラジン誘導体
BR112016024484A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
PL3134395T3 (pl) 2014-04-24 2018-07-31 Novartis Ag Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
PE20170185A1 (es) 2014-05-12 2017-04-01 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas para tratar enfermedades infecciosas
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
EP3174869B1 (en) 2014-07-31 2020-08-19 Novartis AG Combination therapy of a met inhibitor and an egfr inhibitor
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2018029126A1 (en) 2016-08-08 2018-02-15 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2018094392A1 (en) 2016-11-21 2018-05-24 Lupin Inc. Medicament dispenser
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
JP7254076B2 (ja) 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
KR102737185B1 (ko) 2018-01-20 2024-12-05 선샤인 레이크 파르마 컴퍼니 리미티드 치환된 아미노피리미딘 화합물 및 이의 사용 방법
WO2019195711A1 (en) 2018-04-06 2019-10-10 Lupin Inc. Medicament dispenser
US11472765B2 (en) * 2018-04-11 2022-10-18 Mitsubishi Gas Chemical Company, Inc. Production method for 1,4-cyclohexanedicarboxylic acid derivative, 1,4-dicyanocyclohexane and 1,4-bis(aminomethyl)cyclohexane
WO2020058823A1 (en) 2018-09-17 2020-03-26 Lupin, Inc. Dose indicator assembly for a medicament dispenser
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
MX2021015133A (es) 2019-06-10 2022-01-24 Novartis Ag Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia.
CR20220060A (es) 2019-08-28 2022-03-01 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
CN115916305B (zh) 2020-03-25 2025-03-21 陆品公司 多载体药物分配器
CA3173172A1 (en) 2020-03-26 2021-09-30 Christopher D. Kane Cathepsin inhibitors for preventing or treating viral infections
US20230270956A1 (en) 2020-07-23 2023-08-31 Lupin Inc. Dose counter assemblies for medicament dispensers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862239A (en) * 1967-08-22 1975-01-21 Ortho Pharma Corp Aryl substituted cyclohexenecarbinols
US3979444A (en) * 1974-05-28 1976-09-07 The Upjohn Company 4-Arylcyclohexylamines
US4795757A (en) * 1984-09-04 1989-01-03 Rorer Pharmaceutical Corporation Bisarylamines
AU2807192A (en) * 1991-10-02 1993-05-03 Smithkline Beecham Corporation Cyclopentane and cyclopentene derivatives with antiallergic antiinflammatory and tumor necrosis factor inhibiting activity
EP0633771A4 (en) * 1992-04-02 1995-02-22 Smithkline Beecham Corporation Compounds.
EP0633775B1 (en) * 1992-04-02 2000-05-31 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor
JP3192424B2 (ja) * 1992-04-02 2001-07-30 スミスクライン・ビーチャム・コーポレイション アレルギーまたは炎症疾患の治療用化合物

Also Published As

Publication number Publication date
CA2133439C (en) 2005-07-26
CA2133439A1 (en) 1993-10-14
BG62235B1 (bg) 1999-06-30
EP0633776A4 (cg-RX-API-DMAC10.html) 1995-01-25
FI944549A0 (fi) 1994-09-30
CZ239794A3 (en) 1995-05-17
HU9402817D0 (en) 1995-01-30
NO943663L (no) 1994-11-15
SK117194A3 (en) 1995-06-07
FI944549A7 (fi) 1994-11-30
CZ283425B6 (cs) 1998-04-15
GR3036347T3 (en) 2001-11-30
WO1993019749A1 (en) 1993-10-14
AP9600794A0 (en) 1996-04-30
AU677776B2 (en) 1997-05-08
NO943663D0 (no) 1994-09-30
IL105221A0 (en) 1994-08-26
AP519A (en) 1996-08-23
SI9300169B (sl) 2008-04-30
SK279958B6 (sk) 1999-06-11
AU3791093A (en) 1993-11-08
MX9301943A (es) 1994-08-31
US5643946A (en) 1997-07-01
SI9300169A (en) 1993-12-31
US5602157A (en) 1997-02-11
EP0633776A1 (en) 1995-01-18
NO303116B1 (no) 1998-06-02
CN1066436C (zh) 2001-05-30
US5614540A (en) 1997-03-25
IL105221A (en) 2000-01-31
FI944549L (fi) 1994-11-30
HU225869B1 (en) 2007-11-28
HUT70523A (en) 1995-10-30
US5552438A (en) 1996-09-03
AP9300508A0 (en) 1993-04-30
AP516A (en) 1996-08-23
EP0633776B1 (en) 2001-05-09
CN1092406A (zh) 1994-09-21
BG99080A (bg) 1995-08-28

Similar Documents

Publication Publication Date Title
AP516A (en) Pharmaceutical compositions containing novel compounds and their use in treating allergic and inflammatory diseases.
US6300372B1 (en) 3-Cyano-3-(3,4-disubstituted) phenylcyclohexyl-1-carboxylates
EP0634930A1 (en) Compounds useful for treating allergic and inflammatory diseases
EP0633775A1 (en) Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor
EP0636026A1 (en) Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
WO1993019750A1 (en) Compounds useful for treating allergic or inflammatory diseases
WO1993019720A2 (en) Compounds
WO1995009623A1 (en) Anti-allergic, anti-inflammatory compounds, compositions and uses
WO1995009836A1 (en) Cyanocyclohexane compounds, compositions, and uses thereof
WO1995009627A1 (en) Compounds, compositions and treatment of allergies and inflammation therewith
EP0919544B1 (en) Compounds useful for treating allergic and inflammatory diseases
WO1995009837A1 (en) Cyano compounds
HK1063180A (en) Compounds useful for treating allergic and inflammatory diseases
AU675640C (en) Compounds useful for treating allergic or inflammatory diseases
HK1067621A (en) Compounds useful for treating allergic and inflammatory diseases
HK1022467B (en) Compounds useful for treating allergic and inflammatory diseases
AU4527696A (en) 3,3-(disubstituted)cyclohexan-1-one monomers and related compounds
EP0799181A1 (en) 3,3-(disubstituted)cyclohexan-1-carboxylate dimers and related compounds

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired